GBT Announces Upcoming Data Presentations at 61st American Society of Hematology Annual Meeting & Exposition
06 nov. 2019 09h00 HE
|
Global Blood Therapeutics, Inc.
Abstracts Include Three Post-hoc Analyses of Phase 3 HOPE Study Clinical Data Data Further Support the Safety and Efficacy of Voxelotor for Sickle Cell Disease (SCD) Examination of Real-world...
GBT Announces New Employment Inducement Grants
04 nov. 2019 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ: GBT) today announced that on November 1, 2019, the compensation committee of GBT’s...
GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor
21 oct. 2019 08h00 HE
|
Global Blood Therapeutics, Inc.
First of Several Post-hoc Analyses Planned Using HOPE Study Clinical Data Findings Presented in Poster Session at 13th Annual Academy for Sickle Cell and Thalassemia Conference SOUTH SAN FRANCISCO,...
GBT Announces New Employment Inducement Grants
07 oct. 2019 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ: GBT) today announced that on October 1, 2019, the compensation committee of GBT’s board...
GBT Announces Upcoming Presentations at the 47th Annual National Sickle Cell Disease Association of America (SCDAA) Convention
02 oct. 2019 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts related to its sickle cell disease (SCD)...
GBT Announces Participation at the 2019 Cantor Global Healthcare Conference
25 sept. 2019 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Cantor Global Healthcare...
GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease
05 sept. 2019 08h00 HE
|
Global Blood Therapeutics, Inc.
Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements...
GBT Announces New Employment Inducement Grants
04 sept. 2019 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2019, the compensation committee of GBT’s...
GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare Conference
03 sept. 2019 16h05 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Morgan Stanley Global Healthcare...
GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference
03 sept. 2019 08h00 HE
|
Global Blood Therapeutics, Inc.
Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness...